Breadcrumbs

Head and neck - oncology

Definitive Chemoradiation

Protocol Administration at chemotherapy unit level Review date
Head and neck squamous cell carcinoma locally advanced cARBOplatin (weekly) chemoradiation (Part 2 of TPF) Medium March 2021
Head and neck squamous cell carcinoma locally advanced definitive cARBOplatin and fluorouracil chemoradiation Medium 3 September 2022
Head and neck squamous cell carcinoma locally advanced definitive cetuximab chemoradiation Medium June 2022
Head and neck squamous cell carcinoma locally advanced definitive cISplatin (three weekly) chemoradiation Medium June 2022
Head and neck squamous cell carcinoma locally advanced definitive cISplatin (weekly) chemoradiation Medium 3 June 2022

Induction Chemotherapy

Protocol Administration at chemotherapy unit level Review date
Head and neck squamous cell carcinoma locally advanced induction TPF (DOCEtaxel cISplatin fluorouracil) (part 1) Medium September 2022

Nasopharyngeal

Protocol Administration at chemotherapy unit level Review date
Nasopharyngeal locally advanced adjuvant cARBOplatin and fluorouracil (following chemoradiation) Medium 3 March 2020
Nasopharyngeal locally advanced adjuvant cISplatin and fluorouracil (following chemoradiation) Medium 3 September 2020
Nasopharyngeal locally advanced cARBOplatin (weekly) chemoradiation Medium 3 March 2021
Nasopharyngeal locally advanced cISplatin (three weekly) chemoradiation Medium 3 September 2022
Nasopharyngeal locally advanced cISplatin (weekly) chemoradiation Medium 3 March 2020
Nasopharyngeal recurrent or metastatic cISplatin and gemcitabine Medium September 2020
Nasopharyngeal recurrent or metastatic gemcitabine Low March 2021

Post operative chemoradiation

Protocol Administration at chemotherapy unit level Review date
Head and neck squamous cell carcinoma locally advanced post operative cISplatin (three weekly) chemoradiation Medium September 2022
Head and neck squamous cell carcinoma locally advanced post operative cISplatin (weekly) chemoradiation Medium 3 March 2020

Recurrent or metastatic

Protocol Administration at chemotherapy unit level Review date
Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin and fluorouracil Medium 2 September 2020
Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin and PACLitaxel Medium June 2022
Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin fluorouracil and cetuximab Medium - Day 12 Low - Day 8 and 15. Moves to full low risk after completion of cARBOplatin/fluorouracil treatment March 2021
Head and neck squamous cell carcinoma recurrent or metastatic cISplatin (three weekly) and fluorouracil Medium September 2022
Head and neck squamous cell carcinoma recurrent or metastatic ciSplatin and capecitabine Medium June 2022
Head and neck squamous cell carcinoma recurrent or metastatic cISplatin fluorouracil and cetuximab

Medium - Day 12
Low - Day 8 and 15
Moves to low risk after completion of cISplatin treatment

March 2020
Head and neck squamous cell carcinoma recurrent or metastatic methotrexate Low September 2020
Head and neck metastatic nivolumab (flat dosing) Low June 2022
Head and neck metastatic nivolumab (weight based dosing) Low June 2022
Head and neck squamous cell carcinoma recurrent or metastatic PACLItaxel Medium March 2021
Head and neck squamous cell carcinoma recurrent or metastatic pembrolizumab Low June 2022

Salivary gland

Protocol Administration at chemotherapy unit level Review date
Head and neck salivary gland advanced CAP (CYCLOPHOSPHamide DOXOrubicin cISplatin) Medium September 2022
Head and neck salivary gland advanced or metastatic ciSplatin and vinORELBine Medium June 2022

Thyroid

Protocol Administration at chemotherapy unit level Review date
Thyroid locally advanced or metastatic lenvatinib Low June 2022


  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formularydrug includedin the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumabcan be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top